Panel approves amendment to biosimilar coverage bill after debate over WAC vs. net cost reporting
The committee adopted amendments to House Bill 870 requiring insurers to report wholesale acquisition cost and a defined net cost per NDC and allowed regulators to accept net‑cost logic for formulary placement with written notice; the bill was reported favorably as amended.
The full story
House Bill 870, introduced in the House and presented in committee by Brett Mishlin of the Association for Accessible Medicines, would require insurers and PBMs to cover lower‑priced generics or biosimilars when they are available and to avoid using utilization management to block access to lower‑cost alternatives.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
or